Company Encyclopedia
View More
name
Jaguar Health
JAGX.US
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs.
4.654 T
JAGX.USMarket value -Rank by Market Cap -/-

Financial Score

21/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking167/186
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-481.00%E
    • Profit Margin-341.90%E
    • Gross Margin82.74%A
  • Growth ScoreC
    • Revenue YoY12.45%B
    • Net Profit YoY-6.76%C
    • Total Assets YoY-15.38%E
    • Net Assets YoY-72.03%E
  • Cash ScoreC
    • Cash Flow Margin-29.25%D
    • OCF YoY12.45%B
  • Operating ScoreD
    • Turnover0.22D
  • Debt ScoreE
    • Gearing Ratio91.19%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Jaguar Health Announces Preliminary Clinical Trial Results for Crofelemer in Short Bowel Syndrome

    Jaguar Health Inc. announced preliminary results from a clinical trial of crofelemer for short bowel syndrome with intestinal failure. An abstract has been submitted for the Digestive Disease Week® conference in May 2026. Crofelemer has Orphan Drug Designation from the FDA and EMA. Additional trials are ongoing. This information is for informational purposes only and not financial advice.

    Reuters·
    US
    JAGX
    +3.54%
    Reuters·
    US
    JAGX
    +3.54%

    Jaguar Health Issues Pre-Funded Warrants in Exchange for Preferred Stock

    Jaguar Health Inc. has issued pre-funded warrants to purchase common stock in exchange for the cancellation of Series M Preferred Stock held by Iliad Research and Trading, L.P. The warrants allow for immediate exercise at $0.001 per share, with a 9.99% beneficial ownership cap. This transaction was exempt from registration under Section 3(a)(9) of the Securities Act of 1933.

    Reuters·
    US
    JAGX
    +3.54%
    Reuters·
    US
    JAGX
    +3.54%

    U.S. Stock Movement Update: Agape ATP surges 87%, Oriental Culture plummets 79%, multiple stocks show significant movement

    Market Overview of US Stocks in the Last Hour The US stock market has shown a significant sector rotation in the past hour, with technology and pharmaceutical stocks performing particularly well. Small-cap stocks and thematic stocks have experienced large fluctuations, with noticeable capital inflows. Market sentiment is relatively active, with short-term enthusiasm rising, and some individual stocks have shown significant price movements. The stock with the largest abnormal movement in the last hour is Agape ATP, which surged 87.35%, with trading volume significantly increasing and short-term capital inflows evident, leading to heightened market sentiment. Strong stocks include: 1. SMX Security Matters: up 67.70%, with a 10-day increase of 1113.76%, driven significantly by short-term capital. 2. Grande: up 59.08%, with a 5-day increase of 58.77%, gaining market attention. 3. HeartBeam: up 52.91%, with a 6-month increase of 51.28%, showing clear capital inflows. 4. Velo3D: up 38.26%, with increased trading volume and active short-term capital. 5. Mawson Infrastructure: up 37.54%, with increased trading volume and positive market sentiment. 6. Treasure Gbl: up 26.62%, with increased trading volume driven by short-term capital. 7. CapsoVision: up 25.59%, with increased trading volume and heightened market attention. 8. Nextdoor: up 25.34%, reaching a new 60-day high, with noticeable capital inflows

    Tracking Unusual Activity·
    US
    JAGX
    +3.54%
    Tracking Unusual Activity·
    US
    JAGX
    +3.54%

    Jaguar Health Showcases Novel Plant-Based Gastrointestinal Medicines in Latest Corporate Presentation

    Jaguar Health Inc. presented updates on its plant-based medicines for gastrointestinal disorders, highlighting FDA-approved Mytesi for HIV/AIDS-related diarrhea and Canalevia-CA1 for chemotherapy-induced diarrhea in dogs. The OnTarget study was emphasized as a pioneering trial, with future plans for metastatic breast cancer studies and expanded access. The presentation is available online.

    Reuters·
    US
    JAGX
    +3.54%
    Reuters·
    US
    JAGX
    +3.54%

    FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

    Jaguar Health announced the FDA's renewal of conditional approval for Canalevia-CA1, a drug for chemotherapy-induced diarrhea in dogs, extended through December 2026. The confirmatory effectiveness trial is expected to conclude in February 2026. Canalevia-CA1 is available from leading veterinary distributors in the U.S. and is crucial for dogs experiencing CID. The renewal marks the fifth and final year of conditional approval, with full approval contingent on trial results.

    Acceswire·
    US
    JAGX
    +3.54%
    Acceswire·
    US
    JAGX
    +3.54%
    © 2025 Longbridge｜Disclaimer